Company profile
TriSalus Life Sciences, Inc.
NASDAQ: TLSI · Healthcare · Medical - Devices
#445 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
44DFH 41DQ 27GM 85SS 52
v0.1 · 65/100 weight · provisional
↑ growth stability, 3-yr revenue growth · ↓ disclosure history, balance-sheet leverage
Methodology →Revenue TTM
$45.1M
Rev growth YoY (TTM)
+25.2%
Net income (FY)
-$39.2M
Employees
102
as of 2026-08-14
Market cap
$346.7M
as of 2026-08-14
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$45.2M$45.2M2025
Net income-$39.2M-$39.2M2025
Operating income-$26.9M-$26.9M2025
Total assets$35.3M$35.3M2025
Liabilities$69.2M$69.2M2025
Equity-$33.9M-$33.9M2025
Revenue trend
FY2023 – FY2025 · USD
FY23
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is TriSalus Life Sciences, Inc.’s revenue?
TriSalus Life Sciences, Inc. booked $45.2M in FY2025 revenue, growing 53% year over year — faster than most Healthcare companies we track, at a -86.9% net margin.
Peers · Healthcare
Evome Medical Technologies Inc.——Protagonist Therapeutics, Inc.57CSepterna Inc50DPC Group, Inc.——Fennec Pharmaceuticals Inc.61CAquestive Therapeutics, Inc.47DNeighbors
Jefferson →Key facts
CEOMary T. Szela
SectorHealthcare
IndustryMedical - Devices
HeadquartersWestminster, CO
ExchangeNASDAQ: TLSI
Employees102
IPO date2021-02-08
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.